Ask AI
ProCE Banner Activity

ADCs with Alternative HER2 Targeting Mechanisms and Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets

Slideset

Download this slideset to review the latest data on new directions using antibody drug conjugates in HER2-positive breast cancer and beyond.

Released: October 30, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

Director, International Breast Cancer Center (IBCC)
Barcelona, Spain
Director, IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana
Madrid, Spain

Javier Cortes, MD, PhD: consultant/advisor: AbbVie, AstraZeneca, Bioasis, Biocon, BioInvent, BioNTech, Bliss, Boehringer Ingelheim, BridgeBio, Circle, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, ExpreS2ion Biotechnologies, GEMoaB, Gilead, Hexagon, HiberCell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Relay, Reveal Genomics, Roche, Scorpion, Seattle Genetics, Zymeworks; honoraria: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher (paid to institution): Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer, Eisai, F. Hoffmann-La Roche, Guardant, IQVIA, Merck Sharp & Dohme, Pfizer, Piqur, Roche; other financial or material support: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; patent beneficiary: licensed patent: HER2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy, issued patent: pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent.